Jump to content

Leprosy

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 66.23.192.182 (talk) at 02:26, 26 December 2006 (Transmission). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Leprosy
SpecialtyInfectious diseases Edit this on Wikidata
Frequency0.002413966% (world)

Leprosy, also known as Hansen's disease,[1] is an infectious disease caused by a DNA plasmid (transposon, or "ultravirus", a small circle of DNA) carried in Hansen's bacillus (the Mycobacterium leprae bacterium) which is thus the vector. The plasmid can exist separately from the bacterial chromosome, and from the bacterium, when it invades human nerves. Leprosy can eventually cause a variety of skin problems, loss of feeling, and paralysis of the hands and feet.[2]

History

File:Gerhard Hansen.jpg
Gerhard Henrick Armauer Hansen (July 29, 1841 - February 12, 1912)

Although leprosy had been known to affect people for centuries, Gerhard Hansen, a Norwegian physician is widely recognized as the person who first identified the bacterium Mycobacterium leprae as the cause of the disease.[3] Hansen concluded on the basis of epidemiological studies that leprosy had a single specific cause.[3] Between 1870 and 1871, Hansen travelled to Bonn and Vienna to gain the training necessary for him to prove his hypothesis.[3] In 1873, as he announced the discovery of Mycobacterium leprae in the tissues of all sufferers, although he did not claim that they were bacteria, he received little support.[3]

In 1879, Hansen gave tissue samples to Albert Neisser who successfully stained the bacteria and announced his findings in 1880, claiming to have discovered the disease-causing organism.[3] There was some conflict between Neisser and Hansen, Hansen as discoverer of the bacillus and Neisser as identifier of it as the etiological agent.[3]

There are still a few leper colonies around the world, in countries such as India and the Philippines. Western humanitarian and church organizations regularly send relief supplies, including handmade "leper bandages"; bandages knitted or crocheted out of cotton, for greater breathability and durability than traditional gauze. The bandages can also be washed, sterilized and reused, making them more cost-effective as well.

In 2001, government-run leper colonies in Japan came under judicial scrutiny, leading to the determination that the Japanese government had mistreated the patients, and the District Court ordered Japan to pay compensation to former patients.[4] In 2002, a formal inquiry into these colonies was set up, and in March of 2005 the policy was strongly denounced. "Japan's policy of absolute quarantine... did not have any scientific grounds."[5] The inquiry denounced not only the government and the doctors which are involved with the policy but also the court which repeatedly ruled in the favour of the government when the policy was challenged, as well as the media, which failed to report the plight of the victims. There are about 7000 records of forced abortion and sterilisation. In some instances, it was reported that babies were suffocated after birth.

The term "leprosy"

Sufferers of Hansen's disease have historically been known as lepers; however, this term is falling into disuse as a result of the diminishing number of leprosy patients and the pejorative connotations of the term. In fact, the term that is now most widely accepted among people and agencies working in the field of Hansen's Disease is "people affected by Hansen's Disease". The term Tzaraath from the Hebrew Bible is commonly translated as leprosy, although the symptoms of Tzaraath are not entirely consistent with leprosy and might refer to a variety of skin disorders other than Hansen's disease.[6] The term itself first appeared in the English language in the 1300s coming from Greek and Hebrew.[7]

Incidence

Worldwide, one to two million people are permanently disabled because of Hansen's disease. However, new understandings of the cause of the two forms of the disease may allow prevention, for example, by attention to minimising skin pressure points in endemic areas, avoiding sleeping on hard surfaces, general health measures to optimise immune function, etc. India has the greatest number of HD cases, with Brazil second and Myanmar third.

In 1999, the world incidence of Hansen's disease was estimated to be 640,000; in 2000, 738,284 cases were identified. In 1999, 108 cases occurred in the United States. In 2000, the World Health Organization (WHO) listed 91 countries in which Hansen's disease is endemic. India, Myanmar and Nepal contained 70% of cases. In 2002, 763,917 new cases were detected worldwide, and in that year the WHO listed Brazil, Madagascar, Mozambique, Tanzania and Nepal as having 90% of Hansen's disease cases.

According to recent figures from the World Health Organization (WHO), new cases detected worldwide have decreased by approximately 107,000 cases (or 21%) from 2003 to 2004. This decreasing trend has been consistent for the past three years. In addition, the global registered prevalence of HD was 286,063 cases; 407,791 new cases were detected during 2004.

Hansen's disease is tracked passively by the Centers for Disease Control and Prevention. Its prevalence in the United States has remained low and relatively stable. There are decreasing numbers of cases worldwide, though pockets of high prevalence continue in certain areas such as Brazil, South Asia (India, Nepal), some parts of Africa (Tanzania, Madagascar, Mozambique) and the western Pacific.

Aside from humans, other creatures that are known to be susceptible to leprosy include the armadillo, mangabey monkeys, rabbits, and mice (on their footpads).

Transmission

Hansen's Disease (HD) is transmitted by Mycobacterium leprae. The bacillus M. leprae has never been grown in the laboratory. As a result it has been difficult to study the exact mechanisms of pathogenesis. However, the Centers for Disease Control's disease information statement about Hansen's [1] makes the following assertion about the transmission of the disease: "Although the mode of transmission of Hansen's disease remains uncertain, most investigators think that M. leprae is usually spread from person to person in respiratory droplets."

Risk groups

At highest risk are those living in endemic areas with poor conditions such as inadequate bedding, contaminated water and insufficient diet, or other diseases (such as HIV) that compromise immune function. Recent research suggests that there is genetic variation in susceptibility. The region of DNA responsible for this variability is also involved in Parkinson's disease, giving rise to current speculation that the two disorders may be linked in some way at the biochemical level. In addition, men are two times more likely to contract leprosy than women.

Clinical features

The disease affects the skin, nerves and mucous membranes. This chronic non-infectious disease usually affects the skin and peripheral nerves but has a wide range of possible clinical manifestations. Patients are classified as having paucibacillary (tuberculoid leprosy) or multibacillary Hansen's disease (lepromatous leprosy). Paucibacillary Hansen's disease is characterized by one or more hypopigmented skin macules and anaesthetic patches, i.e. damaged peripheral nerves which have been attacked by the human host's immune cells. Multibacillary Hansen's disease is associated with symmetric skin lesions, nodules, plaques, thickened dermis, and frequent involvement of the nasal mucosa resulting in nasal congestion and epistaxis (nose bleeds), but typically no nerve damage. Contrary to popular belief, Hansen's bacillus does not cause rotting of the flesh; rather, a long investigation by Dr. Paul Brand yielded that insensitivity in the limbs extremities was the reason why unfelt wounds or lesions, however minute, lead to undetected deterioration of the tissues, the lack of pain not triggering an immediate response as in a fully functioning body.

Treatment

A very great number of leprosaria, or leper hospitals, sprang up in the middle ages, particularly in England, and there were 250 in England around 1230 A.D. The first recorded leprosarium was in Harbledown. These institutions were run along monastic lines, and while lepers were encouraged to live in these monastic-type establishments, this was for the health of their own souls as well as quarantine. Indeed, in Catholic tradition, those suffering from leprosy were considered to be going through Purgatory on Earth, and for this reason their suffering was considered more holy than the ordinary person's.

Radegund was noted for washing the feet of lepers, and Orderic Vitalis writes of a monk, Ralf, who was so overcome by the plight of the leper that he prayed to catch leprosy himself (which he eventually did). The leper would carry a clapper and bell to warn of his approach, and this was as much to attract attention for charity as to warn people that a diseased person was near. According to the Bible[8], Jesus had not only walked with lepers, but touched and conversed with them, as have many workers since Jesus' time, without acquiring the disease (we now understand that it is not infectious in the ordinary sense) and so in medieval religious society, it was a noble thing to be able to converse and build relationships with the leper.

Dapsone was used to treat leprosy from 1946, but because of low efficiency it was believed necessary to take dapsone for months if not years. Search for more effective medicines led to the discovery of clofazimine and rifampin in the sixties at Novartis. Of the two, rifampin was the most widely adopted. The first study using rifampin to treat leprosy was published in 1970.[9] In 1982 Multi-Drug-Therapy (MDT) was introduced, based on studies published by Shantaram Yawalkar and colleagues.[10] The treatment Yawalkar formulated consisted of dapsone and rifampin combination. The current WHO-recommended treatment schedule for leprosy is 6 months dapsone and rifampicin for paucibacillary leprosy and 12 months dapsone, rifampicin and clofazimin for multibacillary leprosy

Improving detection of the disease is important, as is education about its cause, providing patients with high-quality services, moving people in at-risk areas toward healthier living and fighting social taboos about a disease where, in the past, patients were considered to be "unclean" or "cursed by God" as outcasts. The last issue is important to address, because in such societies, patients may be forced to hide their condition (and thus avoid seeking treatment) in order to avoid discrimination, since the lack of awareness about Hansen's disease leads people to falsely believe that the disease is highly contagious and incurable. Since 1995, the World Health Organization (WHO) has provided all endemic countries with free MDT, supplied through Ministries of Health. In December 2005, an agreement was signed between the WHO and the pharmaceutical company Novartis to extend this free provision until at least the end of 2010. There is no known resistance to MDT drugs.

References

  1. ^ "What is Hansen's disease?". caca.essortment.com. Retrieved 2006-11-10.
  2. ^ "Disabled Village Children - Chapter 26 (Leprosy)". dinf.ne.jp. Retrieved 2006-11-10.
  3. ^ a b c d e f "Gerhard Henrik Armauer Hansen". whonamedit.com. Retrieved 2006-11-10.
  4. ^ "Koizumi apologises for leper colonies". news.bbc.co.uk. Retrieved 2006-11-10.
  5. ^ "Japan's leprosy policy denounced". news.bbc.co.uk. Retrieved 2006-11-10.
  6. ^ ""Tsara'at," Leviticus, and the history of a confusion". ncbi.nlm.nih.gov. Retrieved 2006-11-10.
  7. ^ "Leprosy". Oxford English Dictionary: Second Edition. 1989
  8. ^ Mark 1:40-45
  9. ^ Rees RJ, Pearson JM, Waters MF (1970). "Experimental and clinical studies on rifampicin in treatment of leprosy". Br Med J. 688 (1): 89–92. PMID 4903972.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ Yawalkar SJ, McDougall AC, Languillon J, Ghosh S, Hajra SK, Opromolla DV, Tonello CJ (1982). "Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy". Lancet. 8283 (1): 1199–1202. PMID 6122970.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Further reading

  • Corcos, Michael, "Molecular Biology of H.D. - The Case For The involvement of a Transferable Plasmid". The Star, Volume 41, no. 3, January 1982
  • Icon Health Publications. Leprosy: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. San Diego: Icon Health Publications, 2004. ISBN 0-597-84006-7.
  • Tayman, John The Colony : The Harrowing True Story of the Exiles of Molokai, Simon & Schuster, 2006. Template:Auto isbn
  • IT Conversations Tech Nation interview with author John Tayman (MP3 format; runtime: 00:23:20, 10.7 mb, recorded 2006-02-07)
  • C. Rawcliffe, 'Learning to Love the Leper: aspects of institutional Charity in Anglo Norman England,' Anglo Norman Studies 23 (2001).
  • E. Clark, 'Social Welfare and Mutual Aid in the Medieval Countryside', Journal of British Studies 33 (1994) pp394-396.

Template:Link FA